AF and stroke: why blood thinners matter
Atrial fibrillation raises the risk of stroke roughly fivefold. The good news — modern blood-thinning treatment cuts that risk by about two-thirds, often without the hassle of older medications.
Atrial fibrillation lets blood pool in a small pouch of the heart called the left atrial appendage, where clots can form. If a clot breaks free, it travels to the brain and causes a stroke — often a large, disabling one. Blood-thinning medication (anticoagulation) prevents most of these clots. For nearly all AF patients with even one major risk factor, the stroke prevention benefit substantially outweighs the bleeding risk. The choice today is usually between a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) and the older option, warfarin — DOACs are preferred for most patients.
How AF causes stroke
A normal heart squeezes its upper chambers (the atria) cleanly with each beat. In AF, those upper chambers quiver instead of contracting — and quiet, swirling blood is exactly the kind of blood that forms clots.
Most AF-related clots form in a small finger-shaped pouch off the left atrium called the left atrial appendage. When the atrium isn't contracting properly, blood in this pouch sits almost still. Over hours to days, the conditions inside become ripe for clot formation.
If a clot breaks free, it's swept through the left side of the heart, into the aorta, and onwards into the body's main arteries. The brain receives a substantial share of the blood flow leaving the heart, so brain arteries are the most common destination — causing a stroke.
Why AF strokes are worse
Strokes caused by AF (called cardioembolic strokes) tend to be larger and more disabling than strokes caused by narrowing of brain arteries. The clots are bigger, they block bigger vessels, and they affect bigger areas of brain tissue. Around half of AF-related strokes leave significant lasting disability, and the mortality is higher than for other stroke types.
Who needs anticoagulation
Not everyone with AF has the same stroke risk. The decision to start a blood thinner depends on how many additional risk factors you carry — and the more you have, the stronger the case becomes.
The factors that matter
| Risk factor | Why it raises stroke risk |
|---|---|
| Age 65 or older | Blood vessels stiffen, the atria enlarge, and clotting tendency rises with age. Risk climbs further over 75. |
| Previous stroke or TIA | The single strongest predictor — a previous event marks high baseline risk and warrants anticoagulation in nearly all cases. |
| Heart failure | A weakened heart pumps less efficiently, increasing blood stasis and clot risk. |
| High blood pressure | Chronic hypertension damages vessel walls and enlarges the atria, both of which promote clot formation. |
| Diabetes | Diabetes promotes inflammation and clotting tendency throughout the cardiovascular system. |
| Vascular disease | Previous heart attack, peripheral artery disease, or aortic plaque all signal widespread vascular involvement and higher stroke risk. |
Quick self-recognition
Tick the ones that apply to you. This isn't a clinical score — it's a way to gauge whether your case warrants a focused conversation about stroke prevention with your cardiologist.
How the decision actually gets made
Your doctor formalises this using a stroke-risk score. The Australian and international standard is the CHA₂DS₂-VA score, which translates the factors above into a single number to guide the decision. The score was simplified in 2024 — earlier versions counted female sex as a risk factor, but newer evidence showed it shouldn't be weighted on its own, and current guidelines have dropped it.
| Your situation | Stroke risk category | Anticoagulation |
|---|---|---|
| AF with no other risk factors, under 65 | Low | Usually not required |
| AF with one major risk factor | Moderate | Usually recommended |
| AF with two or more major risk factors | High | Strongly recommended |
DOACs vs warfarin
For decades, warfarin was the only oral blood thinner available for AF. That changed about fifteen years ago with the arrival of the direct oral anticoagulants — DOACs. For most AF patients in Australia today, a DOAC is the preferred choice.
How they compare
| Feature | DOACs | Warfarin |
|---|---|---|
| Examples | Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Lixiana) | Coumadin, Marevan |
| Blood test monitoring | Not required for dosing | INR check every 2–6 weeks, lifelong |
| Onset of action | Hours | Several days |
| Diet restrictions | None significant | Vitamin K-rich foods must be kept consistent |
| Drug interactions | Few | Many — including common antibiotics |
| Bleeding inside the brain | Roughly half the rate of warfarin | Reference |
| Reversal if needed | Yes — specific reversal agents available | Yes — vitamin K and prothrombin complex concentrate |
| Mechanical heart valves | Not suitable | Required |
| Moderate-to-severe mitral stenosis | Not suitable | Required |
| PBS subsidised in Australia | Yes | Yes (lower price) |
Which DOAC tends to be chosen
All four DOACs have been shown in large trials to be at least as effective as warfarin for stroke prevention, with consistently lower rates of bleeding inside the brain and, in many patients, a more favourable overall safety profile than warfarin. The choice between them depends on individual factors including kidney function, age, weight, other medications, and previous bleeding history. Apixaban is the most commonly prescribed in Australia for AF, particularly in older patients, because of its favourable bleeding profile.
Why aspirin isn't enough
If you've been told aspirin alone is your AF stroke prevention, that advice is out of date.
Aspirin works on a different part of the clotting system — platelets — and it's effective against the kind of clots that cause heart attacks (which form on damaged artery walls). AF clots are different. They form in slow-moving pools of blood, and the clotting pathway involved isn't meaningfully interrupted by aspirin.
Multiple large trials have shown that aspirin barely reduces the risk of AF-related stroke, while still carrying a bleeding risk. Modern guidelines — including the 2024 ESC AF guidelines and Australian guidelines — explicitly recommend against using aspirin alone for AF stroke prevention. If you have AF and you're on aspirin only, this is worth raising with your GP or cardiologist.
Bleeding risk — the other side of the equation
Anticoagulation does increase the risk of bleeding. Pretending otherwise wouldn't be useful. The question is whether the bleeding risk outweighs the stroke risk — and for the vast majority of AF patients with stroke risk factors, the answer is clearly no.
What raises bleeding risk
- Older age — particularly over 75
- Poor kidney function — affects how DOACs are cleared from the body and may require dose adjustment
- Previous serious bleeding — particularly from the stomach, bowel, or brain
- Other blood thinners — combining anticoagulation with aspirin or clopidogrel substantially raises bleeding risk
- NSAIDs — ibuprofen, diclofenac, naproxen all increase bleeding risk and should be avoided where possible
- Heavy or binge alcohol use
- Uncontrolled high blood pressure
- Frequent falls — though this is less of a concern than commonly assumed (see below)
Many of these are modifiable. Controlling blood pressure, switching from an NSAID to paracetamol where possible, reducing alcohol, and ensuring kidney function is monitored will all reduce bleeding risk without sacrificing stroke protection.
The falls misconception
One of the most common reasons patients avoid anticoagulation — sometimes encouraged by family or even other doctors — is fear of bleeding from a fall. The arithmetic doesn't support this in most cases. The bleeding risk from a single fall on anticoagulation is real but smaller than commonly assumed, while the stroke risk from stopping anticoagulation continues every day. For the great majority of patients at risk of falls, the net benefit of staying on a blood thinner remains strongly positive.
That said, frailty, repeated falls with head injury, and progressive cognitive decline are situations worth specifically reviewing — your cardiologist will balance these against your individual stroke risk.
Practical day-to-day
If you forget a dose
DOACs have a short half-life — the protection drops off quickly if doses are missed. The general rules:
- Once-daily DOACs (rivaroxaban, edoxaban): if you remember the same day, take it. If it's almost time for the next dose, skip the missed one — never double up.
- Twice-daily DOACs (apixaban, dabigatran): take a missed dose if within 6 hours of when it was due, otherwise skip it. Never double up.
Set a phone reminder if you're prone to forgetting. Consistency matters more than precision to the minute.
Surgery and dental work
Most minor procedures — including most dental work — can be done without stopping a DOAC. For larger procedures, your doctor will advise when to stop and when to restart. The timing depends on the procedure's bleeding risk and your kidney function. Never stop or change your blood thinner without your doctor's input.
Other medications
Some antibiotics, antifungals, and seizure medications can interact with DOACs. Always tell your prescriber you're on a blood thinner. Pharmacists are excellent at picking up interactions — using one regular pharmacy helps.
Alcohol
Moderate alcohol (one to two standard drinks) is generally fine on a DOAC. Heavy or binge drinking raises bleeding risk and is best avoided. Alcohol is also an AF trigger in its own right, so reducing intake has double benefit.
Travel
Carry your medication in your hand luggage, take a list of your medications with generic names, and set phone reminders across time zones. Long-haul flights themselves don't require any special precautions — anticoagulation actually reduces (not increases) the risk of flight-related clots.
When to seek urgent help
When bleeding risk is too high: LAA occlusion
For a small group of AF patients, long-term anticoagulation isn't possible — usually because of recurrent serious bleeding, a previous brain haemorrhage, or specific blood disorders. For these patients, an alternative exists: left atrial appendage occlusion.
The procedure uses a small device — the Watchman is the best-known — that is placed inside the left atrial appendage via a catheter threaded up from the leg. The device seals off the pouch from the rest of the heart, so even if a clot were to form there, it can't escape into the circulation. Over several weeks, tissue grows over the device.
After successful placement and a short period of anticoagulation to allow healing, most patients can stop long-term blood thinners — with the timing and any ongoing antiplatelet treatment guided by follow-up imaging and specialist advice. LAA occlusion isn't a first-line option — anticoagulation remains preferable for the vast majority. But for patients who genuinely can't take a blood thinner, it offers meaningful stroke prevention without ongoing bleeding risk.
The procedure is available at major Sydney centres including Westmead Hospital and is typically considered after detailed discussion between cardiology, neurology, and the patient.
Will I be on this forever?
For most patients, yes. Anticoagulation in AF is generally lifelong, for two reasons.
First, the underlying risk factors that drove the decision in the first place — age, hypertension, diabetes, heart failure — don't go away. If anything, they tend to accumulate with time.
Second, and importantly: even after successful treatment that restores normal rhythm — including catheter ablation — AF can recur silently. Episodes that produce no symptoms are still capable of causing strokes. Most cardiologists therefore continue anticoagulation based on the original stroke risk profile, regardless of whether sinus rhythm has been restored.
The patients who can sometimes stop
A small subset of patients can reasonably consider stopping anticoagulation: younger people, low original stroke risk, sustained sinus rhythm after ablation, no other vascular risk factors, and willing to undertake periodic rhythm monitoring. This is always an individual decision with your cardiologist.
Frequently asked questions
I feel completely fine. Do I really need a blood thinner?
The decision to anticoagulate doesn't depend on how you feel — it depends on your stroke risk profile. Many patients with AF feel well right up until the day they have a stroke. The whole point of anticoagulation is to prevent that first event. If your risk factors put you in the moderate or high category, treatment is recommended regardless of symptoms.
Can I just take aspirin instead?
No. Aspirin is not effective for AF stroke prevention. It's an entirely different category of medication that works on a different part of the clotting system. Current Australian and international guidelines specifically recommend against using aspirin alone for this purpose. If you're on aspirin alone for AF, raise it with your doctor.
What's the "safest" DOAC?
All four DOACs are safer than warfarin for most patients in terms of bleeding inside the brain. Among themselves, the differences are smaller and depend on individual factors. Apixaban has the most favourable overall bleeding profile in head-to-head data, particularly in older patients, which is why it's the most commonly prescribed DOAC for AF in Australia. The right choice for you depends on kidney function, age, weight, other medications, and personal preference.
I'm worried about bleeding. How do I weigh the risk?
It's a fair worry, and you're not alone in having it. The honest framing is this: stroke risk from untreated AF is generally several times larger than the bleeding risk from anticoagulation. For most patients with even one major stroke risk factor, the net benefit clearly favours treatment. Your cardiologist can give you specific numbers for your situation, and importantly, many of the things that raise bleeding risk are modifiable.
Can I drink alcohol on a blood thinner?
Moderate alcohol is generally fine — one to two standard drinks. Heavy or binge drinking increases bleeding risk and should be avoided. Alcohol is also a known trigger for AF episodes in many patients, so reducing intake has the double benefit of fewer episodes and lower bleeding risk.
What if I forget a dose?
For twice-daily DOACs (apixaban, dabigatran), take the missed dose if it's within 6 hours of when it was due — otherwise skip it. For once-daily DOACs (rivaroxaban, edoxaban), take it if you remember the same day, otherwise skip. Never double up. Phone reminders are the simplest way to prevent missed doses.
I'm having surgery next month — what should I do?
Don't stop your blood thinner on your own. The surgeon and your cardiologist will agree on when to stop, when to restart, and whether any bridging treatment is needed. The timing depends on the procedure's bleeding risk and your kidney function. Most minor procedures, including most dental work, don't require stopping.
Are there reversal options if I have a serious bleed?
Yes. Specific reversal agents exist for the DOACs — andexanet alfa for apixaban and rivaroxaban, idarucizumab for dabigatran. Warfarin reversal uses vitamin K and prothrombin complex concentrate. All major Australian hospitals stock these and use them for serious bleeding events.
The bottom line
The two questions every AF patient should be able to answer with their doctor are: am I on the right protection against stroke? and are the modifiable bleeding risks being managed? Get those two right and the rest of AF care follows.
References & further reading
- Guideline Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). DOI: 10.1093/eurheartj/ehae176 Eur Heart J. 2024;45(36):3314–3414.
- Guideline Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. DOI: 10.5694/mja18.00646 Med J Aust. 2018;209(8):356–362.
- Trial analysis Granger CB, Alexander JH, McMurray JJV, et al. (ARISTOTLE Investigators) Apixaban versus warfarin in patients with atrial fibrillation. DOI: 10.1056/NEJMoa1107039 N Engl J Med. 2011;365(11):981–992.
- Consensus Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. DOI: 10.1016/S0140-6736(13)62343-0 Lancet. 2014;383(9921):955–962.
- Trial analysis Reddy VY, Sievert H, Halperin J, et al. (PROTECT-AF / PREVAIL Investigators) Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. DOI: 10.1001/jama.2014.15192 JAMA. 2014;312(19):1988–1998.
- Patient body Heart Foundation Australia Atrial fibrillation — patient information. heartfoundation.org.au/your-heart/atrial-fibrillation
- Patient body NPS MedicineWise Anticoagulants — what to know about your medicine. nps.org.au/consumers/anticoagulant-medicines
AF and worried about stroke?
Dr Reza Moazzeni provides comprehensive AF stroke-risk assessment at Westmead — risk stratification, bleeding-risk review, kidney function check, and an individualised anticoagulation plan in one consultation. A GP referral is required.
Book a Consultation